Literature DB >> 8765008

OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand.

A al-Shamkhani1, M L Birkeland, M Puklavec, M H Brown, W James, A N Barclay.   

Abstract

OX40, a member of the tumor necrosis factor (TNF) receptor/nerve growth factor (NGF) receptor superfamily was first identified as a marker of activated rat CD4+ cells with the MRC OX40 monoclonal antibody (mAb). A ligand for OX40 (called OX40 ligand or OX40L) has recently been identified and has sequence similarity to TNF. Mouse OX40L-immunoglobulin fusion protein (OX40L-Ig) binds to activated mouse CD4+ and CD8+ cells (Baum, P. R. et al., EMBO J. 1994. 13: 3992) suggesting that OX40 could have a differential pattern of expression on mouse and rat T cells. This, however, did not rule out the presence of an alternative receptor on CD8+ cells that also binds the OX40L. We have compared the binding of the MRC OX40 mAb with that of OX40L-Ig to activated rat lymph node cells and show that both recognize the same protein, namely OX40 which is expressed on CD4+ and CD4+ CD8 alpha+ cells, but not on CD4-CD8+ cells. We have raised a new mAb (MRC OX86) using recombinant mouse OX40 protein and show by two-color flow cytometry that mouse OX40 is expressed on CD4 and CD8 single-positive cells. In addition, the new MRC OX86 mAb, unlike the MRC OX40 mAb, did not block binding of the OX40L. We conclude that OX40 is differentially expressed on activated mouse and rat T cells and is the sole receptor for the OX40L.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8765008     DOI: 10.1002/eji.1830260805

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  35 in total

1.  Essential role of OX40L on B cells in persistent alloantibody production following repeated alloimmunizations.

Authors:  Hiroshi Kato; Hidefumi Kojima; Naoto Ishii; Hidenori Hase; Yutaka Imai; Takashi Fujibayashi; Kazuo Sugamura; Testuji Kobata
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

Review 2.  T-cell activation in the intestinal mucosa.

Authors:  Dina Montufar-Solis; Tomas Garza; John R Klein
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

3.  The IKK-neutralizing compound Bay11 kills supereffector CD8 T cells by altering caspase-dependent activation-induced cell death.

Authors:  Seung-Joo Lee; Meixiao Long; Adam J Adler; Robert S Mittler; Anthony T Vella
Journal:  J Leukoc Biol       Date:  2008-10-15       Impact factor: 4.962

4.  OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.

Authors:  Sarah Buchan; Teresa Manzo; Barry Flutter; Anne Rogel; Noha Edwards; Lei Zhang; Shivajanani Sivakumaran; Sara Ghorashian; Ben Carpenter; Clare Bennett; Gordon J Freeman; Megan Sykes; Michael Croft; Aymen Al-Shamkhani; Ronjon Chakraverty
Journal:  J Immunol       Date:  2014-11-17       Impact factor: 5.422

5.  Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.

Authors:  Nicholas P Morris; Carmen Peters; Ryan Montler; Hong-Ming Hu; Brendan D Curti; Walter J Urba; Andrew D Weinberg
Journal:  Mol Immunol       Date:  2007-03-19       Impact factor: 4.407

6.  Type I IFN-dependent T cell activation is mediated by IFN-dependent dendritic cell OX40 ligand expression and is independent of T cell IFNR expression.

Authors:  Jonathan S Kurche; Catherine Haluszczak; Jennifer A McWilliams; Phillip J Sanchez; Ross M Kedl
Journal:  J Immunol       Date:  2011-12-07       Impact factor: 5.422

Review 7.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

Review 8.  Chemokine receptors and co-stimulatory molecules: unravelling feline immunodeficiency virus infection.

Authors:  Brian J Willett; Margaret J Hosie
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

Review 9.  The role of OX40-mediated co-stimulation in T-cell activation and survival.

Authors:  William L Redmond; Carl E Ruby; Andrew D Weinberg
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

10.  Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype.

Authors:  Daniel Hirschhorn-Cymerman; Sadna Budhu; Shigehisa Kitano; Cailian Liu; Feng Zhao; Hong Zhong; Alexander M Lesokhin; Francesca Avogadri-Connors; Jianda Yuan; Yanyun Li; Alan N Houghton; Taha Merghoub; Jedd D Wolchok
Journal:  J Exp Med       Date:  2012-09-24       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.